Skip to content

Abstract IA003: Targeting the antigenic landscape that emerges after KRAS inhibition for PDAC immunotherapy

Sep 2026 · Cancer Research · Vol 86, pp. IA003-IA003 · 0 citations

TL;DR

Targeting the antigenic landscape that emerges after KRAS inhibition for PDAC immunotherapy holds significant translational potential as KRAS inhibitors are poised to become a mainstay in PDAC treatment and treatment induced antigens may serve as the foundation for rationally designed combination immunotherapies.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is predicted to emerge as the second leading cause of cancer related death by 2030. Many treatment options that are successful in other cancer types, including immune checkpoint blockade, are generally ineffective in PDAC and the 5-year survival rate has remained stagnant for decades. Mutant KRAS, the most common oncogenic driver in PDAC, was previously considered “undruggable” but recent advances have led to the development of potent KRAS inhibitors (KRASi) that have demonstrated unprecedented clinical activity. While KRASi has shown early promise, inherent and acquired resistance remains a significant clinical barrier. Notably, preclinical studies have shown that KRASi induces T cell mediated anti-tumor immunity, but the mechanisms driving this phenomenon are unknown. T cell recognition of cancer occurs through the presentation of antigens on Major Histocompatibility Complexes (MHC-I and MHC-II). Despite the recognition that KRASi drives adaptive immunity in PDAC, the functional interplay between KRASi and antigen presentation has not been explored. Therefore, we hypothesized that KRASi reshapes both the MHC-I and MHC-II antigen landscape in the PDAC tumor microenvironment to drive anti-tumor immune responses. To address this, we utilized a collection of novel preclinical mouse models and patient derived organoids (PDOs) to identify treatment induced patterns of antigen presentation on MHC-I and MHC-II on malignant and stromal cells. KRASi induced the presentation of numerous epitopes on both MHC-I and MHC-II, many of which are known to be associated with adaptive resistance to KRASi. We also observed that tumors that exhibited strong responses to KRASi induced MHC-II, indicating a favorable tumor immune microenvironment marked by malignant cell derived MHC-II. Many KRASi induced MHC-II epitopes were found to be highly immunogenic, suggesting that CD4+ T cells targeting MHC-II epitopes are an underappreciated source of immunotherapeutic potential in PDAC. Cross species analysis of MHC epitopes induced by KRASi in human and mouse cells revealed conserved antigenic landscapes for future therapeutic development. These studies hold significant translational potential as KRAS inhibitors are poised to become a mainstay in PDAC treatment and treatment induced antigens may serve as the foundation for rationally designed combination immunotherapies. Alex Jaeger, Emma Adhikary, Andrew Deonarine, Emily Brennan, Christopher Polera, Emily Paul, Miguel Xiao Barbero, John Powers, Antonio Amelio. Targeting the antigenic landscape that emerges after KRAS inhibition for PDAC immunotherapy [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr IA003.

View source

Similar papers

Sep 2026

Abstract B087: Impact of RAS inhibition on T cell maturation in the PDAC microenvironment

It is suggested that pharmacologic and genetic KRAS inhibition differentially remodel the intratumoral T cell compartment, whereas both induce similar T cell changes within the liver premetastatic niche.

Lauren Gerbereux, Rashmi Kumar, E. Lasse-Opsahl et al. · 0 citations
Oct 2026

Opening the window for immunotherapy in pancreatic cancer.

KRAS inhibitors (KRASi) are reshaping the treatment of aggressive tumors such as pancreatic ductal adenocarcinoma (PDAC), but it is appreciated that patients will eventually acquire resistance through multiple pathways. To avoid this outcome, there is much effort to identify combination therapies that take advantage of...

Margaret E. Haerr, Katelyn T. Byrne · 0 citations
#protein folding Sep 2026

Abstract B095: Discovery of treatment-associated peptide antigens for targeted immunotherapies in pancreatic ductal adenocarcinoma

This work provides a framework for identifying actionable treatment-induced peptide antigens and supports rational combination strategies pairing KRAS/RAS inhibitors with T cell-based immunotherapies, including BiTE, CAR-pMHC, TCR-T, and cancer vaccine approaches.

Wei-Xia Kang, Allison Glynn, Harshabad Singh et al. · 0 citations
Sep 2026

Abstract B074: Comparative analysis of next-generation KRAS inhibitors in patient derived pancreatic cancer organoids

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a five-year survival rate below 10%. Due to aggressiveness and lack of early detection methods, patients are often diagnosed at an advanced stage, leaving few therapeutic options. This emphasizes the need for a deeper understanding of the mo...

P. Winckler, Georg Vladimirov, Lennart Herrlich et al. · 0 citations
Sep 2026

Abstract PR012: Encoding adaptive mechanisms of resistance to KRAS inhibition in pancreatic cancer

This study defines adaptive resistance mechanisms to KRAS-targeted therapy in PDAC, revealing both cell-state-dependent RTK rewiring and a conserved SFK adaptive signaling axis and provides a mechanistic rationale for either KRAS/pan-RAS or pan-RAS/SFK co-inhibition as strategies to improve responses to KRAS-targeted t...

Qing-Xiang Lin, Bo-Kai Song, C. Sander et al. · 1 citation
Sep 2026

Abstract IA007: Getting ahead of the tumor: Interception approaches for pancreas cancer

Pancreatic ductal adenocarcinoma (PDAC) emerges from precursor lesions (PanINs and IPMNs) that harbor mutations in the KRAS oncogene. Once thought to be untargetable, the KRAS oncoprotein can now be inhibited with small molecule compounds that bind to either the active or inactive form of the protein. KRAS inhibitors...

Ben Z. Stanger, Minh T. Than, Lucie Dequiedt et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.